This Biotech Company Looks To Be Targeting A New Drug To Treat NASH, The Leading Cause of Liver Transplants
SponsoredPsoriasis Drug Providers Looking Over Shoulders At Upcoming Competitor?
SponsoredA New Oral Therapy for Psoriasis Could Be Coming Soon
SponsoredPRIOR TO PHASE III PSORIASIS DATA RELEASE CAN FITE REPORTS THAT PICLIDENOSON DESTROYS PATHOLOGICAL SKIN CELLS IN VITRO
SponsoredCan-Fite BioPharma Ltd. Recent News
Can-Fite to Conduct Investor Meetings during the J.P. Morgan Healthcare Conference
Sponsored
Dawson James - Can-Fite (CANF) Buy Rated - Expected Milestones
Sponsored
CAN-FITE ISSUES LETTER TO SHAREHOLDERS
Sponsored
FOLLOWING COMPLETE CLEARANCE OF CANCER LESIONS IN ADVANCED LIVER CANCER PATIENT, CAN-FITE IS FILING PATENT APPLICATIONS FOR THE TREATMENT OF VARIOUS ADVANCED SOLID TUMORS
Sponsored
Positive Data from Phase IIa Can-Fite NASH Study Published in Leading Peer Reviewed Scientific Journal
Sponsored
Piclidenoson From Can-Fite Biopharma Shows New, Promising Developments For Psoriasis Treatment
Sponsored
Earnings Roundup: iAnthus, Can-Fite, Organigram, Bluma Wellness, Auxly